Low-Dose Antibiotic Prophylaxis Induces Rapid Modifications of the Gut Microbiota in Infants With Vesicoureteral Reflux
- PMID: 34222145
- PMCID: PMC8247656
- DOI: 10.3389/fped.2021.674716
Low-Dose Antibiotic Prophylaxis Induces Rapid Modifications of the Gut Microbiota in Infants With Vesicoureteral Reflux
Abstract
Background and Objectives: Maturation of the gut microbiota (GM) in infants is critically affected by environmental factors, with potential long-lasting clinical consequences. Continuous low-dose antibiotic prophylaxis (CAP) is the standard of care for children with vesicoureteral reflux (VUR), in order to prevent recurrent urinary tract infections. We aimed to assess short-term GM modifications induced by CAP in infants. Methods: We analyzed the GM structure in 87 infants (aged 1-5 months) with high-grade VUR, previously exposed or naïve to CAP. Microbial DNA was extracted from stool samples. GM profiling was achieved by 16S rRNA gene-based next-generation sequencing. Fecal levels of short- and branched-chain fatty acids were also assessed. Results: 36/87 patients had been taking daily CAP for a median time of 47 days, while 51/87 had not. In all patients, the GM was predominantly composed by Bifidobacteriaceae and Enterobacteriaceae. Subgroup comparative analysis revealed alterations in the GM composition of CAP-exposed infants at phylum, family and genus level. CAP-exposed GM was enriched in members of Enterobacteriaceae and Bacteroidetes, especially in the genera Bacteroides and Parabacteroides, and showed a trend toward increased Klebsiella, often associated with antibiotic resistance. In contrast, the GM of non-CAP children was mostly enriched in Bifidobacterium. No differences were found in fatty acid levels. Conclusions: In infants with VUR, even a short exposure to CAP definitely alters the GM composition, with increased relative abundance of opportunistic pathogens and decreased proportions of health-promoting taxa. Early low-dose antibiotic exposure might bear potential long-term clinical risks.
Keywords: antibiotic prophylaxis; children; gut microbiota; urinary tract infection; vesicoureteral reflux.
Copyright © 2021 Morello, D'Amico, Serafinelli, Turroni, Abati, Fiori, Baskin, Yalcinkaya, Jankauskiene, Pennesi, Zurowska, Becherucci, Drozdz, Mekahli, Krzemien, La Scola, Taranta-Janusz, Mehls, Schaefer, Candela and Montini.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Impact of continuous low-dose antibiotic prophylaxis on growth in children with vesicoureteral reflux.J Pediatr Urol. 2018 Aug;14(4):325.e1-325.e7. doi: 10.1016/j.jpurol.2018.07.007. Epub 2018 Jul 23. J Pediatr Urol. 2018. PMID: 30181099
-
The Swedish infant high-grade reflux trial: Study presentation and vesicoureteral reflux outcome.J Pediatr Urol. 2017 Apr;13(2):130-138. doi: 10.1016/j.jpurol.2016.08.026. Epub 2016 Oct 24. J Pediatr Urol. 2017. PMID: 27889221 Clinical Trial.
-
Antibiotic prophylaxis for prevention of urinary tract infections in the first year of life in children with vesicoureteral reflux diagnosed in the workup of antenatal hydronephrosis: a systematic review.Pediatr Nephrol. 2020 Sep;35(9):1639-1646. doi: 10.1007/s00467-020-04568-6. Epub 2020 Apr 30. Pediatr Nephrol. 2020. PMID: 32350666
-
Retrospective Analysis to Determine the Optimal Timing to Discontinue Continuous Antibiotic Prophylaxis in Patients with Primary Vesicoureteral Reflux.Urol Int. 2019;102(4):462-467. doi: 10.1159/000497312. Epub 2019 Mar 27. Urol Int. 2019. PMID: 30917379
-
Contemporary Management of Vesicoureteral Reflux.Eur Urol Focus. 2017 Apr;3(2-3):181-188. doi: 10.1016/j.euf.2017.08.012. Epub 2017 Sep 12. Eur Urol Focus. 2017. PMID: 28918954 Review.
Cited by
-
Long-Term Effectiveness of Onabotulinum Toxin-A in a Combined Total Endoscopic Management of Pediatric Vesicoureteral Reflux in Neurogenic Bladder Dysfunction.Toxins (Basel). 2025 Jun 29;17(7):330. doi: 10.3390/toxins17070330. Toxins (Basel). 2025. PMID: 40711141 Free PMC article.
-
Therapeutic Management of Children with Vesicoureteral Reflux.J Clin Med. 2023 Dec 31;13(1):244. doi: 10.3390/jcm13010244. J Clin Med. 2023. PMID: 38202251 Free PMC article.
-
Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial.Nutrients. 2022 Oct 10;14(19):4208. doi: 10.3390/nu14194208. Nutrients. 2022. PMID: 36235860 Free PMC article. Clinical Trial.
-
Comparison between Short Therapy and Standard Therapy in Pediatric Patients Hospitalized with Urinary Tract Infection: A Single Center Retrospective Analysis.Children (Basel). 2022 Oct 28;9(11):1647. doi: 10.3390/children9111647. Children (Basel). 2022. PMID: 36360375 Free PMC article.
-
Effects of Malted Rice Amazake on Constipation Symptoms and Gut Microbiota in Children and Adults with Severe Motor and Intellectual Disabilities: A Pilot Study.Nutrients. 2021 Dec 14;13(12):4466. doi: 10.3390/nu13124466. Nutrients. 2021. PMID: 34960021 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources
Miscellaneous